In this study, epigallocatechin gallate decreased peritoneal neutrophil infiltration as well as the levels of neutrophil cytosolic factor 1, IL-6, IL-1β, monocyte chemoattractant protein-1 (MCP-1) in peritoneal lavage fluid, and amyloid A levels in serum, thus suggesting that NLRP3 blockade could represent a viable pharmacological strategy for the management of peritoneal inflammation associated with gout. Here, CCL2 is linked to gout.